Phytocannabinoids and bone health.

Palmer H.; Roopchand D. · Current osteoporosis reports · 2026

**Background & Methods** This is a narrative review summarizing recent studies investigating the effects of phytocannabinoids on bone homeostasis and musculoskeletal health. The review synthesizes in vitro data, rodent studies, and clinical evidence to evaluate how cannabis and hemp-derived products impact bone metabolism. **Key Findings** • Cannabidiol (CBD) is the most extensively studied phytocannabinoid for bone health, with in vitro evidence demonstrating that it inhibits osteoclast activity while promoting osteoblast function, supporting bone formation over resorption. • Preclinical rodent models show CBD may effectively manage bone loss in osteoporosis and periodontitis, reduce fracture-related pain, and accelerate fracture healing processes. • The single available clinical study demonstrated that a medical cannabis product reduced bone turnover markers in healthy adults, suggesting potential therapeutic effects; however, other phytocannabinoid isolates and multi-phytocannabinoid extracts exhibit varying and inconsistent effects on bone metabolism. **Dosage & Administration** Not reported. The review indicates that optimal dose, timing, and route of administration remain to be determined through future research. **Safety & Adverse Effects** Not reported. The abstract does not discuss safety profiles or adverse effects associated with phytocannabinoid use for bone health. **Evidence Quality** This review is limited by the predominance of in vitro and animal model data, with minimal human clinical evidence. Only one clinical trial is cited, severely limiting the ability to draw firm conclusions about efficacy and safety in human populations. The heterogeneity of phytocannabinoid preparations (isolates versus extracts with multiple cannabinoids) complicates interpretation of results. The mechanistic basis appears sound—phytocannabinoids interact with the endocannabinoid system, which regulates bone metabolism—yet translation to clinical practice remains unclear. Significant gaps exist regarding dose-response relationships, long-term effects, optimal administration routes, and comparative efficacy against standard osteoporosis treatments. The increasing prevalence of cannabis use raises urgent questions about potential negative effects on musculoskeletal health that require systematic investigation. Additional well-designed randomized controlled trials in diverse populations are essential before phytocannabinoids can be recommended clinically for bone health management.

More recent cannabis research